Abstract:<p>Recent advances in structural biology and computational techniques have revealed allosteric mechanisms for an abundance of targets leading to the establishment of rational design of allosteric modulators as a new avenue for drug discovery. Considering that allostery is an intrinsic property of the protein conformational ensemble, allosteric drug design has the potential to develop into an innovative approach to modulate the dysregulation of therapeutic targets that are considered to be undruggable at their orthosteric site, explore strategic design opportunities to tackle new chemical space, or develop mutant-specific therapies to target mutations occurring far from the enzyme active site. Traditionally, allosteric drug discovery has been performed through high-throughput screening or through serendipitous discoveries; however, recent developments in structure-based and ligand-based methods have led to exciting advancements of designing bioactive allosteric ligands rationally. In this review article, we highlight the advantages and disadvantages of allosteric modulators and present structure-based and ligand-based drug design methodologies for the identification of allosteric binding sites and allosteric modulators. We also illustrate representative studies for the design allosteric modulators for proteins belonging to a wide range of protein families, also considering irreversible binding with covalent allosteric modulators. Additionally, we analyze challenges and successes in the rational design of allosteric inhibitors and activators. Finally, we present the future of rational allosteric ligand design with newly built computational tools that we expect to be applied in future studies, concluding to theoretical and practical guidelines for allosteric ligand design strategies and identify knowledge gaps that need to be addressed to improve efficiency in allosteric drug design.</p><p>This article is categorized under: </p><ul class="plain-list"><li>Structure and Mechanism > Computational Biochemistry and Biophysics</li><li>Structure and Mechanism > Molecular Structures</li></ul>

Designed dualsteric modulators: A novel route for drug discovery

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Computational elucidation of allosteric communication in proteins for allosteric drug design

Rational design of allosteric modulators: Challenges and successes

Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions

Allosteric drugs: New principles and design approaches

Discovery of Novel Allosteric Modulators Targeting an Extra-Helical Binding Site of GLP-1R Using Structure- and Ligand-Based Virtual Screening

Computational insights into diverse binding modes of the allosteric modulator and their regulation on dopamine D1 receptor

Drug design targeting active posttranslational modification protein isoforms

Recent Advances In The Rational Drug Design Based On Multi-Target Ligands

Multiple Target Drug Design Using LigBuilder 3

Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug development

Design of an allosterically modulated doxycycline and doxorubicin drug-binding protein

Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy.

Design of allosteric modulators that change GPCR G protein subtype selectivity

Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance

DNA-modularized construction of bivalent ligands precisely regulates receptor binding and activation

Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery

Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Functional selectivity and dualsteric/bitopic GPCR targeting

Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.